First, the reality: Retatrutide is an investigational drug in Phase 3 clinical trials. It is not approved by Health Canada, the FDA, or any regulatory agency. It cannot be legally purchased from any pharmacy, online retailer, or compounding pharmacy. Anyone selling "retatrutide" is offering an unregulated product.

Pathway 1: Enroll in a clinical trial

This is the safest and most direct way to access retatrutide in Canada. The TRIUMPH Phase 3 program has sites across Canada.

Best Practice Clinical trial participation is free. You receive the investigational drug, medical monitoring, and contribute to research that will determine whether retatrutide becomes an approved treatment. There are no hidden costs, and you can withdraw at any time.

How to find and enroll:

  1. Search: Visit ClinicalTrials.gov and filter for "Recruiting" studies in Canada
  2. Check eligibility: Each trial has specific inclusion/exclusion criteria (BMI range, age, medical conditions)
  3. Contact the site: Reach out to the study coordinator listed on the trial page
  4. Get a referral: Your family physician can refer you to a trial site — bring the clinicaltrials.gov listing with you
  5. Screening visit: If you appear eligible, you'll attend a screening visit for full evaluation

Search Canadian trials ↗

Pathway 2: Health Canada Special Access Programme (SAP)

The SAP allows physicians to request access to unapproved drugs for individual patients when:

  • Conventional therapies have failed, are unsuitable, or are unavailable
  • The patient has a serious or life-threatening condition
  • The drug is not available through a clinical trial
  • The manufacturer agrees to supply the drug
Important: SAP access is not guaranteed. It requires:
  • A physician willing to submit the application
  • Clinical justification for why this specific drug is needed
  • Manufacturer (Eli Lilly) cooperation to supply the drug
  • Health Canada review and approval
This is not a routine prescription — it's an exceptional pathway for cases where no approved alternative exists.

If your physician believes SAP access may be appropriate, they can find application procedures at Health Canada's SAP page. The SAP guidance document provides detailed eligibility criteria and application instructions.

Pathway 3: Wait for regulatory approval

This is the most likely path for most Canadians. If the TRIUMPH Phase 3 program produces positive results:

  1. Eli Lilly will submit to Health Canada for a Notice of Compliance (NOC)
  2. Health Canada reviews safety, efficacy, and manufacturing quality data
  3. If approved, retatrutide can be prescribed by Canadian physicians and dispensed by pharmacies
  4. Provincial and private drug plans will evaluate coverage (this can take additional months to years)

Realistic timeline: If everything goes well, retatrutide could potentially receive Health Canada approval in 2026-2027. This is an estimate — actual timelines depend on trial results and regulatory review speed.

What to avoid

Warning: The online "research chemical" and grey-market peptide industry is unregulated. Here's what to be extremely cautious about.

Online sellers of "retatrutide"

Websites and social media accounts selling "retatrutide for research purposes" are not offering pharmaceutical-grade product. These are unregulated peptides with:

  • Unknown purity (may contain impurities, degradation products, or contaminants)
  • Unknown potency (the stated dose may be inaccurate)
  • Unknown identity (the vial may contain a different peptide entirely)
  • No sterility assurance (injecting non-sterile substances carries serious infection risk)
  • No medical supervision or adverse event reporting

Compounding pharmacies

Compounding pharmacies may offer to prepare "retatrutide" formulations. However:

  • The raw ingredient is not the same as pharmaceutical-grade retatrutide
  • Health Canada has issued warnings about compounded GLP-1 products
  • There is no quality standard or oversight for compounded retatrutide preparations
  • Adverse events from compounded products are not tracked in the same way as approved drugs
Our Recommendation We strongly advise against purchasing any product marketed as retatrutide from online sellers or compounding pharmacies. The risks of unregulated injectable products — infection, contamination, incorrect dosing, allergic reactions, and unknown long-term consequences — far outweigh any potential benefit. Wait for clinical trial access or regulatory approval.